Trial Profile
A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs PEG-haemoglobin carbon monoxide (Primary)
- Indications Sickle cell anaemia; Vaso-occlusive crisis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Prolong Pharmaceuticals
- 22 May 2018 Status changed from recruiting to completed.
- 12 Dec 2017 Interim results of a study assessing levels of RBC sickling following treatment and association with pain scoring presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 08 Nov 2017 According to a Prolong Pharmaceuticals media release, results from this trial will be presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH).